No Data
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Laekna, Inc.'s (HKG:2105) Market Cap Dropped HK$392m Last Week; Individual Investors Who Hold 36% Were Hit as Were Institutions
Laekna Successfully Completes Phase I Trial Of Obesity Drug
LAEKNA-B (02105.HK): The Phase I single ascending dose study (SAD study) of LAE102 for the treatment of obesity has been successfully completed.
Gelonghui, January 13 - LAEKNA-B (02105.HK) announced that the group has successfully completed the phase I single ascending dose study ("SAD study") for LAE102 targeting obesity treatment. A total of 64 healthy subjects were recruited for the SAD study, with an average BMI of 23.2±2.2 kg/m2, including 5 intravenous dosing cohorts and 3 subcutaneous dosing cohorts. The results of the SAD study lay the foundation for our upcoming phase I multiple ascending dose study ("MAD study") in China and the phase I clinical study in collaboration with Eli Lilly and Co in the USA.
Laikai Pharmaceutical's self-developed PI3Kα inhibitor was selected for 2024 SABCS and has the best potential in its class
SHANGHAI, December 12, 2024 /PRNewswire/ -- Lai Kai Pharmaceutical (2105.HK) announced today that the company's self-developed result “a variant inhibitor targeting multiple types of PI3Kα mutants — pre-clinical study of LAE118” has been selected for the 2024 San Antonio Breast Cancer Symposium (SABCS) and will present relevant research in the form of a poster at a seminar in San Antonio, Texas, USA on December 13 data. “Very happy to come to Kay
Hong Kong stock concept tracking | Eli Lilly and Co will invest 3 billion USD to expand its production base in the usa, as global demand for weight loss drugs exceeds supply (including concept stocks).
Eli Lilly and Co (LLY.US) will invest 3 billion dollars to expand its production base in the USA.
